share_log

HC Wainwright & Co. Reiterates Buy on United Therapeutics, Maintains $300 Price Target

Benzinga ·  Feb 22 19:48

HC Wainwright & Co. analyst Andrew Fein reiterates United Therapeutics (NASDAQ:UTHR) with a Buy and maintains $300 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment